Praxis Precision Medicines, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Praxis Precision Medicines, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $8.55M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.45M | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | $0 | Mar 5, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($303.27M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2024 | ($58.68M) | Feb 28, 2025 |
| FY2024 | Sep 30, 2024 | ($51.91M) | Feb 28, 2025 |
| FY2024 | Jun 30, 2024 | ($32.68M) | Feb 28, 2025 |
| FY2024 | Mar 31, 2024 | ($39.55M) | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | ($26.88M) | Feb 28, 2025 |
| FY2024 | Sep 30, 2023 | ($24.63M) | Feb 28, 2025 |
| FY2024 | Jun 30, 2023 | ($34.31M) | Feb 28, 2025 |
| FY2024 | Mar 31, 2023 | ($37.46M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($41.17M) | Mar 5, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($326.20M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($200.17M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($126.37M) | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | ($214.99M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($167.33M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | ($61.97M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($35.79M) | Mar 17, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $267.12M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $152.41M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $86.77M | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | $155.04M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $120.26M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $44.98M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $29.56M | Mar 17, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($249.07M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($131.76M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($111.14M) | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | ($185.04M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($124.55M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | ($52.62M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($33.42M) | Mar 17, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.0K | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $50.0K | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | $444.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $1.05M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $103.0K | Mar 17, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $937.91M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $483.11M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $87.95M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $115.13M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $292.75M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $303.18M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $47.69M | Mar 17, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.77M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $37.66M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $18.28M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $39.02M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $41.94M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.72M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $7.58M | Mar 17, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $878.14M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $445.45M | Feb 19, 2026 |
| FY2024 | Sep 30, 2024 | $382.67M | Feb 28, 2025 |
| FY2024 | Jun 30, 2024 | $419.10M | Feb 28, 2025 |
| FY2024 | Mar 31, 2024 | $229.68M | Feb 28, 2025 |
| FY2025 | Dec 31, 2023 | $69.67M | Feb 19, 2026 |
| FY2024 | Sep 30, 2023 | $86.76M | Feb 28, 2025 |
| FY2024 | Jun 30, 2023 | $105.63M | Feb 28, 2025 |
| FY2024 | Mar 31, 2023 | $64.47M | Feb 28, 2025 |
| FY2025 | Dec 31, 2022 | $76.11M | Feb 19, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.14B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($836.74M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($653.92M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($530.64M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($316.62M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | ($149.55M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($81.01M) | Mar 17, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $357.33M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $215.37M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $81.30M | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | $61.62M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $138.70M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $296.61M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $44.82M | Mar 17, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (18) | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | (69) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | (7) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (18) | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | (69) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | (7) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 19.42M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 8.79M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 3.29M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 45.30M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | 38.27M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 1.62M | Mar 17, 2021 |